SEC Form 4 · accession 0001213900-17-010639
REGENERX BIOPHARMACEUTICALS INC · RGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sinaf S.A.
10% Owner
Period of report
Oct 13, 2017
Accepted (ET)
Oct 17, 2017 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000707511
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 13, 2017 | C | 1,671,296 | — | A | 11,382,703 | D | |
| Common StockF2 | Oct 13, 2017 | J | 266,667 | — | A | 11,649,370 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory Note (right to buy)F1 | $0.15 | Oct 13, 2017 | C | 1,671,296 | D | Oct 19, 2012 | — | Common Stock | 1,671,296 | 0 | D |
| Common Stock Warrant (right to buy)F2 | $0.15 | Oct 13, 2017 | J | 266,667 | D | Apr 19, 2013 | Oct 19, 2017 | Common Stock | 266,667 | 0 | D |
Explanation of responses
- F1On October 13, 2017, the reporting person converted a $200,000 convertible promissory note (the "Note"), purchased from the issuer in a private placement on October 19, 2012, and accrued interest of $50,694.44 into common stock. The Note and accrued interest were convertible into common stock at the option of the holder at any time prior to repayment of the Note at a conversion price of $0.15 per share. Interest accrued on the unpaid principal amount at a rate equal to 5% per annum.
- F2On October 13, 2017, the reporting person exercised a warrant issued by the issuer to the reporting person in consideration of the reporting person's purchase of the Note at an exercise price of $0.15 per share of common stock.